Compare CIO & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIO | XOMA |
|---|---|---|
| Founded | 2013 | 1981 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.5M | 322.7M |
| IPO Year | 2014 | N/A |
| Metric | CIO | XOMA |
|---|---|---|
| Price | $6.99 | $26.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $63.25 |
| AVG Volume (30 Days) | ★ 347.5K | 267.6K |
| Earning Date | 02-19-2026 | 11-12-2025 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.82 |
| Revenue | ★ $163,795,000.00 | $47,106,000.00 |
| Revenue This Year | $0.32 | $77.29 |
| Revenue Next Year | $3.20 | $34.91 |
| P/E Ratio | ★ N/A | $32.40 |
| Revenue Growth | N/A | ★ 118.02 |
| 52 Week Low | $4.19 | $18.35 |
| 52 Week High | $7.01 | $39.92 |
| Indicator | CIO | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 67.11 | 42.93 |
| Support Level | $6.94 | $25.30 |
| Resistance Level | $6.97 | $28.61 |
| Average True Range (ATR) | 0.01 | 1.34 |
| MACD | 0.00 | 0.32 |
| Stochastic Oscillator | 90.00 | 38.40 |
City Office REIT Inc is a real estate investment trust. It is focused on acquiring, owning, and operating high-quality office properties located predominantly in Sun Belt markets. The principal objective of the company is to provide attractive risk-adjusted returns to its investors over the long-term through a combination of dividends and capital appreciation. Its properties includes: Pima Center, SanTan, Park Tower, Intellicenter, Intellicenter, Denver Tech, Canyon Park, AmberGlen and many. The company own these office buildings in the metropolitan areas of Dallas, Denver, Orlando, Phoenix, Portland, Raleigh, San Diego, Seattle, and Tampa.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.